Description

Procaps Group, S.A. operates as a globally integrated healthcare and pharmaceutical enterprise. The company is actively involved in the development, production, and distribution of branded prescription medications across numerous therapeutic domains, including women's health, pain management, dermatology, digestive wellness, growth and development, cardiovascular health, ophthalmology, central nervous system disorders, and respiratory ailments. Additionally, it supplies a range of pharmaceuticals for hospital use, such as antibiotics, anticoagulants, personal protective equipment, immunosuppressants, oncology treatments, and analgesics. Procaps also offers an extensive portfolio of over-the-counter (OTC) consumer healthcare products, covering approximately ten distinct therapeutic categories. These include gastrointestinal health, skincare, cough and cold remedies, pain relief, urological support, and various vitamins, minerals, and dietary supplements. Further specialized areas encompass anti-infective agents, cardiovascular medications, feminine care products, cutaneous antimycotics, hormonal treatments, metabolic and endocrine solutions, nervous system drugs, ophthalmic preparations, osteoarticular therapies, and respiratory aids. Beyond its core pharmaceutical offerings, the company provides comprehensive diabetes management solutions, including blood glucose meters, telemonitoring systems, oral antidiabetics, and insulin delivery devices, alongside cosmeceuticals and other related products. Furthermore, Procaps extends its capabilities to third-party pharmaceutical companies by offering contract drug development and manufacturing services, with a specific expertise in soft gelatin capsule technologies. Founded in 1977, the company is headquartered in Luxembourg City, Luxembourg.